Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 21, 2020

View Archived Issues

Another obstacle to universal flu vaccine

ORIC Pharmaceuticals' OP-4954 displays selective glucocorticoid receptor antagonism

Promising preclinical data for novel lymph node targeting COVID-19 vaccine

Phosphodiesterase PDE3A and PDE3B inhibitors described by Bayer, The Broad Institute

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical patent ADORA2A/B antagonists

Jiangsu Chia Tai Tianqing Pharmaceutical discovers HBV capsid assembly inhibitors

New opioid receptor ligands identified at Yangtze River Pharmaceutical

Esteve presents dual sigma1 and mu-opioid receptor ligands

Genmab initiates first-in-human study of GEN-1044

Takeda starts enrollment in first-in-human trial of TAK-102

Enrollment ongoing in phase I/II study of TAEK-VAC-HerBy vaccine

First participant vaccinated in phase III study of MenABCWY meningitis vaccine candidate

Tankyrase inhibition with OM-153 shows potential for immuno-oncology

Ascletis completed bridging study of ASC-18 FDC pill for the treatment of hepatitis C

Repurposing of low-cost generic nafamostat as COVID-19 therapy

First healthy volunteer dosed in phase I clinical program of IMU-856

Positive early data for lead mRNA COVID-19 vaccine candidate BNT-162b2

Orally active STING agonists stimulate innate immunity

FDA approves Kesimpta for the treatment of relapsing multiple sclerosis

Imfinzi receives Japanese approval for the treatment of extensive-stage SCLC

First-in-human proof-of-concept trial for HBV treatment ALG-010133 begins

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.